About Breast cancer metastasis-suppressor 1-like protein
Breast cancer metastasis-suppressor 1-like protein (BRMS1L) is a protein
from Homo sapiens identified by UniProt accession
Q5PSV4, 323 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Breast cancer metastasis-suppressor 1-like protein |
|---|
| UniProt accession | Q5PSV4 |
|---|
| Gene | BRMS1L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 323 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- ulcerative colitis · score 0.19
- hemoglobin measurement · score 0.10
- hematocrit · score 0.10
- BMI-adjusted hip circumference · score 0.10
- thyroid carcinoma · score 0.09
- cancer · score 0.08
- neoplasm · score 0.08
- alkaline phosphatase measurement · score 0.08
- goiter · score 0.08
- non-small cell lung carcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5PSV4-F1 | alphafold | PREDICTED | 80.61 | — |
Amino-acid sequence (323 residues)
MPVHSRGDKK ETNHHDEMEV DYAENEGSSS EDEDTESSSV SEDGDSSEMD DEDCERRRME CLDEMSNLEK QFTDLKDQLY KERLSQVDAK LQEVIAGKAP EYLEPLATLQ ENMQIRTKVA GIYRELCLES VKNKYECEIQ ASRQHCESEK LLLYDTVQSE LEEKIRRLEE DRHSIDITSE LWNDELQSRK KRKDPFSPDK KKPVVVSGPY IVYMLQDLDI LEDWTTIRKA MATLGPHRVK TEPPVKLEKH LHSARSEEGR LYYDGEWYIR GQTICIDKKD ECPTSAVITT INHDEVWFKR PDGSKSKLYI SQLQKGKYSI KHS
Explore Breast cancer metastasis-suppressor 1-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets